Why Pharmacogenetics Matters

'It is an unfortunate fact that medicines are currently not as effective as they could be in an average of around 50% of patients, and in certain indications the success rate is even lower. This is why Roche is systematically pursuing personalised medicine'1

'Biotech/pharma and personalized medicine manufacturers who are early adopters of personalized medicine stand to receive significant ROI as highly effective targeted therapies displace traditional therapies'2

'To support the patient recruitment and multi-center trial requirements for more targeted study populations, companies may begin to develop research and information collaboratives with affiliates, academic medical centers and research organisations'2

^{1. Severin Sachwan, CEO, Roche (Burrill & Co Biotech 2009 - Life Science: Navigating the Sea Change)}

^{2. Deloitte Centre for Health Solutions}